Includes data for head and neck cancer, biliary tract cancer and esophageal cancers More: Merck KGaA announces new results for bifunctional immunotherapy M7824 Source: News
read moreSanofi’s Dupixent picked up its important asthma approval on Friday, setting the drug up for a multibillion-dollar peak sales boost, according to an analyst. More: Sanofi's Dupixent set for .5B in peak asthma sales after scoring winning label: analyst Source:
read moreMSD’s immunotherapy improved overall survival by up to 39% More: Strong results for Keytruda in head and neck cancer Source: News
read moreBristol-Myers Squibb presented a raft of results for its Opdivo-Yervoy immuno-oncology combo across multiple tumor types at the European Society for Medical Oncology meeting. But results it didn’t present stole the weekend spotlight. More: Bristol-Myers' Opdivo-Yervoy combo hits a regulatory
read moreMerck KGaA has opened a new distribution center as it continues to streamline its manufacturing and build up the production site at its headquarters in Darmstadt, Germany. More: Merck KGaA opens M distribution facility at German headquarters Source: fierce
read moreAfter batting aside efficacy questions in head and neck cancer, Merck’s Keytruda is back with a new batch of positive data, this time in previously untreated patients. More: ESMO18: Merck's Keytruda, alone and in combo, makes its case for earlier
read more© 1994 - 2026 B.M. Pharmaceuticals